Latest Commercial Revenue News

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Temple & Webster defied a tough consumer backdrop to post record FY26 revenue of A$665 million and is targeting a substantial 50-80% EBITDA increase in FY27 under new CEO Susie Sugden.

Brisbane Broncos expect a 33% increase in half-year net profit before tax to $11.57 million, driven by higher crowd attendance and merchandise sales despite reduced ARLC funding and rising costs.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Brisbane Broncos capped a landmark 2025 season with both NRL and NRLW premiership victories, driving a 20.5% revenue surge and a 36% profit increase. The club rewarded shareholders with increased dividends amid record crowds and expanded community programs.

NoviqTech (ASX: NVQ) advances its biochar carbon removal strategy with a key non-binding MoU covering 70% of credits from its Great Barrier Reef project, targeting 2026 commercial milestones.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Tlou Energy has crossed a significant threshold by generating initial revenue from its Lesedi coal bed methane gas through the newly operational Kala Data Centre in Botswana. The milestone validates its integrated gas-to-power model while funding constraints and technical challenges remain key hurdles.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.